Discovery of novel liver X receptor inverse agonists as lipogenesis inhibitors
- 1 November 2020
- journal article
- research article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 206, 112793
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
- National Key Research and Development Program of China
This publication has 30 references indexed in Scilit:
- Liver X receptors in lipid signalling and membrane homeostasisNature Reviews Endocrinology, 2018
- The challenges and promise of targeting the Liver X Receptors for treatment of inflammatory diseasePharmacology & Therapeutics, 2018
- Transcriptional regulation of hepatic lipogenesisNature Reviews Molecular Cell Biology, 2015
- The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitisMolecular Metabolism, 2015
- A Liver-Selective LXR Inverse Agonist That Suppresses Hepatic SteatosisACS Chemical Biology, 2012
- Liver X receptor biology and pharmacology: new pathways, challenges and opportunitiesTrends in Pharmacological Sciences, 2012
- GPS2-dependent corepressor/SUMO pathways govern anti-inflammatory actions of LRH-1 and LXRβ in the hepatic acute phase responseGenes & Development, 2010
- Parallel SUMOylation-Dependent Pathways Mediate Gene- and Signal-Specific Transrepression by LXRs and PPARγMolecular Cell, 2007
- LXR, a nuclear receptor that defines a distinct retinoid response pathway.Genes & Development, 1995
- Ubiquitous receptor: a receptor that modulates gene activation by retinoic acid and thyroid hormone receptors.Proceedings of the National Academy of Sciences, 1994